Summit Clinical Trials for Ivonescimab (SMT112)
Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in the U.S. & EU.* Brings two validated mechanisms in oncology1,2,3 into ONE novel tetravalent molecule.
Phase 3 Study: NCT05184712
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment. Learn more.
Phase 3 Study: NCT05899608
A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer. Learn more.
Ivonescimab Mechanism of Action
For More Information on Ivonescimab click here
Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
For additional information on the HARMONi or the HARMONi-3 clinical trials, please contact medinfo@smmttx.com
References
- Manegold C, et al. J Thorac Oncol 2017;12(2):194-207.
- Pardoll, D. Nat Rev Cancer 2012;12(4):252-64.
- Tamura R, et al. Med Oncol 2020;37(1):2.
*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).
